APA

Overstreet A. M., LaTorre D. L., Abernathy-Close L., Murphy S. F., Rhee L., Boger A. M., Adlaka K. R., Iverson A. M., Bakke D. S., Weber C. R. & Boone D. L. (20190723). The JAK inhibitor ruxolitinib reduces inflammation in an ILC3-independent model of innate immune colitis. : Mucosal immunology.

Chicago

Overstreet A M, LaTorre D L, Abernathy-Close L, Murphy S F, Rhee L, Boger A M, Adlaka K R, Iverson A M, Bakke D S, Weber C R and Boone D L. 20190723. The JAK inhibitor ruxolitinib reduces inflammation in an ILC3-independent model of innate immune colitis. : Mucosal immunology.

Harvard

Overstreet A. M., LaTorre D. L., Abernathy-Close L., Murphy S. F., Rhee L., Boger A. M., Adlaka K. R., Iverson A. M., Bakke D. S., Weber C. R. and Boone D. L. (20190723). The JAK inhibitor ruxolitinib reduces inflammation in an ILC3-independent model of innate immune colitis. : Mucosal immunology.

MLA

Overstreet A M, LaTorre D L, Abernathy-Close L, Murphy S F, Rhee L, Boger A M, Adlaka K R, Iverson A M, Bakke D S, Weber C R and Boone D L. The JAK inhibitor ruxolitinib reduces inflammation in an ILC3-independent model of innate immune colitis. : Mucosal immunology. 20190723.